The treatment of lung cancer often combines systemic therapy (chemotherapy, immunotherapy), radiation therapy, and surgery. In advanced stages novel therapies (e.g., bispecific antibodies) may be an option. These treatments as well as disease, age-related changes, and comorbid conditions (e.g., emphysema, heart disease) can have adverse effects on respiratory function. Lung cancer treatment is becoming more complex, and patients are treated in many clinical settings, therefore effective communication between thoracic oncologists and RTs is essential to ensure patients receive appropriate care to reduce symptom burden and improve quality of life.

This activity is supported through an educational grant from